$1.53
+4.79%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.53
From 52W high−71.40%
Volume249466.00
Market cap$154.10M
P/E (TTM)—
P/S (TTM)2.7x
Div yield—
Key dataSep 18, 2026
Open
$1.53
From 52W high
−71.40%
Volume
249466.00
Market cap
$154.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
P/E (TTM)
—
RSI (14)
22.6
MomentumView details →
1D Return
+4.79%
YTD Return
−68.60%
SummaryUpdated Jun 1, 2026
Cellectis S.A. (NASDAQ:CLLS) is a French clinical-stage biotechnology company founded in 1999 and headquartered in Paris. The company specializes in developing gene-edited immunotherapy treatments for cancer, particularly focusing on allogeneic CAR-T cell therapies that can be manufactured at scale and used across multiple patients. Cellectis has evolved from its early gene-editing platform origins to become a leading developer of "off-the-shelf" cancer immunotherapies, with multiple clinical programs in various stages of development and a significant strategic partnership with pharmaceutical giant AstraZeneca established in 2024.
Similar companies
Latest newsMore news →
SBS Law announced a fraud investigation into Cellectis S.A. and invited CLLS investors to join it.12h agoHolzer & Holzer, LLC announced an investigation into whether Cellectis S.A. complied with federal securities laws after Cellectis said it would exit development of lasme-cel and eti-cel.3d agoCellectis announced that its board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.6d ago